Literature DB >> 26275386

[Anesthesia management in implantation of baroreceptor stimulators].

T Werner1, L Lebar2, S Wittmann2, A Keyser3, M Fischer4, J Schmidli5, B M Graf2, Y A Zausig2.   

Abstract

Baroreceptor stimulators are novel implantable devices that activate the carotid baroreceptor reflex. This results in a decrease in activity of the sympathetic nervous system and inhibition of the renin-angiotensin-aldosterone system. In patients with drug-resistant hypertension, permanent electrical activation of the baroreceptor reflex results in blood pressure reduction and cardiac remodeling. For correct intraoperative electrode placement at the carotid bifurcation, the baroreceptor reflex needs to be activated several times. Many common anesthetic agents, such as inhalation anesthetics and propofol dampen or inhibit the baroreceptor reflex and complicate or even prevent successful placement. Therefore, a specific anesthesia and pharmacological management is necessary to ensure successful implantation of baroreceptor reflex stimulators.

Entities:  

Keywords:  Anesthesia; Baroreceptor reflex; Carotid sinus; Electric stimulation therapy; Hypertension

Mesh:

Year:  2015        PMID: 26275386     DOI: 10.1007/s00101-015-0061-3

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  27 in total

1.  The recovery profile of baroreflex control of heart rate after isoflurane or sevoflurane anesthesia in humans.

Authors:  G Nagasaki; M Tanaka; T Nishikawa
Journal:  Anesth Analg       Date:  2001-11       Impact factor: 5.108

Review 2.  Vaccination against high blood pressure.

Authors:  Duncan J Campbell
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Blood pressure and heart rate changes during physical activity upon heart rate feedback-controlled electrical carotid sinus nerve stimulation.

Authors:  T K Peters; H E Koralewski; E Zerbst
Journal:  Int J Cardiol       Date:  1989-03       Impact factor: 4.164

4.  Baroreflex activation therapy in patients with pre-existing implantable cardioverter-defibrillator: compatible, complementary therapies.

Authors:  Navid Madershahian; Maximilian Scherner; Jochen Müller-Ehmsen; Marcel Halbach; Tilman Hickethier; Ralf Velden; Yeong-Hoon Choi; Jens Wippermann; Thorsten Wahlers
Journal:  Europace       Date:  2014-02-13       Impact factor: 5.214

5.  Opioids and central baroreflex control: a site of action in the nucleus tractus solitarius.

Authors:  F J Gordon
Journal:  Peptides       Date:  1990 Mar-Apr       Impact factor: 3.750

6.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

Authors: 
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

7.  Rheos Baroreflex Hypertension Therapy System to treat resistant hypertension.

Authors:  Ingrid J M Scheffers; Abraham A Kroon; Jan H M Tordoir; Peter W de Leeuw
Journal:  Expert Rev Med Devices       Date:  2008-01       Impact factor: 3.166

8.  Prolonged activation of the baroreflex produces sustained hypotension.

Authors:  Thomas E Lohmeier; Eric D Irwin; Martin A Rossing; David J Serdar; Robert S Kieval
Journal:  Hypertension       Date:  2004-01-05       Impact factor: 10.190

9.  Treating resistant hypertension with new devices.

Authors:  H Wienemann; F Meincke; L Kaiser; C H Heeger; M W Bergmann
Journal:  Minerva Cardioangiol       Date:  2014-06       Impact factor: 1.347

10.  Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study.

Authors:  Edoardo Gronda; Gino Seravalle; Gianmaria Brambilla; Giuseppe Costantino; Andrea Casini; Ali Alsheraei; Eric G Lovett; Giuseppe Mancia; Guido Grassi
Journal:  Eur J Heart Fail       Date:  2014-07-28       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.